Carfilzomib, lenalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: Results of ENDURANCE phase III trial
Bortezomib (btz) combined with lenalidomide (len) and dexamethasone (dex) (VRd) is a standard initial therapy for NDMM. Carfilzomib (cfz), a next-generation proteasome inhibitor, in combination with len-dex (KRd) has shown higher efficacy in phase II trials. This randomized phase III trial was designed to examine if KRd improves progression free survival (PFS) compared to VRd in NDMM (current results), and whether indefinite maintenance with len improves OS compared with two-year maintenance (to be analyzed once data matures).
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA3
Presenter:
Shaji Kumar
Oncology